Peptides that bind only the α4β1 integrin (SSTN210-233) or VEGFR2 (SSTN214-240) act as competitive inhibitors of myeloma or endothelial cell invasion with possible roles as cancer therapeutics. Here, KDR is linked to plasma cell myeloma.